Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIPLET: Switching from Clopidogrel to Prasugrel in ACS
NCT01115738Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2010
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of prasugrel in acute coronary syndrome (ACS) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation at 6 hours. Started May 2010; status: completed.
02
Drugs
prasugrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT01115738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01115738.